Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2984390 | 0.89 | MAPT (0.59) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL10397625 | 0.81 | KMT2A (0.43) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL8538892 | 0.76 | CYP1A2 (0.62) | KMT2AMAPTCYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL9640561 | 0.76 | CYP1A2 (0.66) | KMT2AMEN1MAPTCYP1A2ALDH1A1 | |
| SCHEMBL10688602 | 0.72 | SMN1; SMN2 (0.57) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL11188965 | 0.72 | USP2 (0.52) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL4070154 | 0.72 | MAPT (0.70) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL23750083 | 0.71 | SMARCA2 (0.51) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL12317147 | 0.71 | HTT (0.49) | KMT2AMEN1MAPTRAB9ACYP1A2 | |
| SCHEMBL1292324 | 0.71 | MAPT (0.44) | KMT2AMEN1MAPTRAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781582-B2 | Process for the preparation of 2-amino-[1,2,4]triazolo[1,5-a]pyrimidines | DOW AGROSCIENCES LLC (US) | 2010-08-24 | — | — | US | disclosed |
| EP-1699794-B1 | PROCESS FOR THE PREPARATION OF TRIAZOLOPYRIMIDINES | DOW AGROSCIENCES LLC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070238873-A1 | Process for the Preparation of Triazolopyrimidines | CORTEVA AGRISCIENCE LLC | 2007-10-11 | — | — | US | disclosed |
| EP-1699794-A1 | PROCESS FOR THE PREPARATION OF TRIAZOLOPYRIMIDINES | Dow AgroSciences LLC (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005063753-A1 | PROCESS FOR THE PREPARATION OF TRIAZOLOPYRIMIDINES | DOW AGROSCIENCES LLC (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238873-A1 | Process for the Preparation of Triazolopyrimidines | NUDT1, ABL1, DPYD | KMT2A 1044/4885MEN1 4566/4885MAPT 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.